Klin Farmakol Farm. 2017;31(2):18-22 | DOI: 10.36290/far.2017.031

Summary

Pavel Štourač
Neurologická klinika LF MU a FN Brno

We use for the treatment of relapsing-remitting course of multiple sclerosis the drugs with different mechanisms of action anddifferent clinical efficacy and safety profile. The treatment algorithm involves current clinical status of the patient and long-termefficacy and safety of the drug. The available drugs are as following; interferon beta-1a (IFNβ-1a), interferon beta-1b (IFNβ-1b),glatiramer acetate(GA), teriflunomide, dimethylfumarate, fingolimode, natalizumab and alemtuzumab.

Keywords: treatment of multiple sclerosis, efficacy, risks

Received: April 15, 2019; Accepted: April 16, 2019; Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P. Summary. Klin Farmakol Farm. 2017;31(2):18-22. doi: 10.36290/far.2017.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci 2004; 101: 14593-14598. Go to original source... Go to PubMed...
    2. Cross AH, Naismith RT. Established and novel disease - modifying treatments in multiple sclerosis J Int Med 201: 275(4): 350-363. Go to PubMed...
    3. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889-897. Go to original source... Go to PubMed...
    4. Wee Yong V, Chabot S, Stuve O. Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-689. Go to original source... Go to PubMed...
    5. Nifkar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-? in multiple sclerosis, overall and by drug and disease type. Clin Ther. 2010; 32(11): 1871-1888. Go to original source... Go to PubMed...
    6. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Eng J Med 2012; 365: 1293-1303. Go to original source...
    7. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061. Go to original source... Go to PubMed...
    8. EMA, Press release. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri, 26.2.2016.
    9. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097. Go to original source... Go to PubMed...
    10. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med 2012; 367: 1098-1107. Go to original source... Go to PubMed...
    11. dostupné na http://www.slideshare.net/gavingiovannoni/natalizumab-benefit-risk-update-q3-2015.
    12. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM Investigation of the mechanisms of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128: 260-270. Go to original source... Go to PubMed...
    13. Huggins A, Sergott RC. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Curr Opin Ophthalmol. 2011; 22(6): 447-450. Go to original source... Go to PubMed...
    14. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection and management. Neurology 2012; 78: 672-680. Go to original source... Go to PubMed...
    15. O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014; 83: 78-86. Go to original source... Go to PubMed...
    16. Wolinsky JS, Borresen TE, Dietrich WD, Sidi Y, Steinerman JR, Knappertz, Kolodny S; GLACIER Study Group: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple2011; 22: 447-450.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.